1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedarplus.ca under the Company’s profile.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development
November 3, 2014
Resverlogix Announces Annual General Meeting Voting Results
October 8, 2014
Resverlogix Corporate Update Conference Call & Webcast Announcement
October 1, 2014
RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus
September 2, 2014
Resverlogix Corp. Closes Additional $30 million from Citibank Loan
August 15, 2014
Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan
August 13, 2014
RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus
July 23, 2014
Resverlogix Secures an Additional $30 million from Citibank Loan
July 3, 2014
Resverlogix Closes $2.3 million Private Placement
June 11, 2014
Leading Life Science Publication SciBX Highlights RVX-208
May 21, 2014
Cleveland Clinic Presents RVX-208 Data at American College of Cardiology (ACC) Conference in Washington DC March 31, 2014
March 31, 2014
Resverlogix Update
March 17, 2014
Resverlogix Board Update
February 11, 2014
Resverlogix Conference Call & Webcast Announcement
February 6, 2014
Resverlogix Announces Combined RVX-208 findings from SUSTAIN & ASSURE Phase 2b Trials
January 15, 2014
Publications Confirm RVX-208 is a Unique Selective BET Bromodomain Antagonist
January 2, 2014